BRIEF-Merck sees accelerating declines for Remicade, due to biosimilars
February 03, 2016 at 09:14 AM EST
* Says it expects global Januvia/Janumet sales to rise in 2016, when excluding negative impact of strong dollar
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.